WO2019004449A1 - 医薬組成物 - Google Patents
医薬組成物 Download PDFInfo
- Publication number
- WO2019004449A1 WO2019004449A1 PCT/JP2018/024884 JP2018024884W WO2019004449A1 WO 2019004449 A1 WO2019004449 A1 WO 2019004449A1 JP 2018024884 W JP2018024884 W JP 2018024884W WO 2019004449 A1 WO2019004449 A1 WO 2019004449A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- pemafibrate
- salt
- solvate
- lactose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Definitions
- the present invention relates to a pharmaceutical composition and the like.
- Pemafibrate (chemical name: (2R) -2- [3-( ⁇ 1,3-benzoxazol-2-yl [3- (4-methoxyphenoxy) propyl] amino ⁇ methyl) phenoxy] butanoic acid represented by ((2R) -2- [3-([1,3-benzoxazol-2-yl [3- (4-methoxyphenoxy) propyl] amino] methyl) phenoxy] butanoic acid), international common name: Pemafibrate or salts thereof Or their solvates have excellent PPAR ⁇ agonist activity, exhibit effects such as lowering plasma triglyceride levels and increasing HDL cholesterol, and are useful for the prevention and treatment of dyslipidemia (hyperlipidemia) It is known that it is useful for preventing and treating (patent document 1, non-patent documents 1 and 2) and NAFLD (nonalcoholic fatty liver disease) (patent document 2).
- a compound useful as an active ingredient of a pharmaceutical is usually formulated and supplied as a pharmaceutical composition, it is supplied from the viewpoint of reliably exerting the expected medicinal effect and avoiding unexpected side effects. It is extremely important to ensure a constant quality without variation among lots, for the pharmaceutical composition to be used.
- an object of the present invention is to provide a pharmaceutical composition which contains pemafibrate or a salt thereof or a solvate thereof and is excellent in homogeneity.
- the pharmaceutical composition containing a solvate (hereinafter sometimes referred to simply as “component (A)” in the present specification) further comprises a disaccharide represented by lactose (hereinafter referred to as the present specification) Were found to improve the content uniformity of pemafibrate in a pharmaceutical composition simply by including "the component (B)".
- the present invention provides the following components (A) and (B): (A) pemafibrate or a salt thereof or a solvate thereof; (B) disaccharides; Providing a pharmaceutical composition comprising
- the present invention also relates to pemafibrate or a salt thereof or a solvate thereof in a pharmaceutical composition comprising the step of including a disaccharide in a pharmaceutical composition containing pemafibrate or a salt thereof or a solvate thereof.
- the present invention provides a method for improving the content uniformity of
- content uniformity of pemafibrate in a pharmaceutical composition can be improved, and a pharmaceutical composition with excellent homogeneity can be provided.
- pemafibrate or a salt thereof or a solvate thereof is exemplified by pemafibrate (chemical name: (2R) -2- [3-( ⁇ 1,3-benzoxazol-2-yl [3- (4-Methoxyphenoxy) propyl] amino ⁇ methyl) phenoxy] butanoic acid ((2R) -2- [3-([1,3-benzoxazol-2-yl [3- (4-methoxyphenoxy) propyl) amino] methyl In addition to phenoxy] butanoic acid), international common name: Pemafibril) itself, pharmaceutically acceptable salts of Pemafibrate, and further, Pemafibrate and pharmaceutically acceptable salts thereof, water, alcohol (eg, ethanol), etc.
- the pharmaceutically acceptable salt is not particularly limited, and examples thereof include acid addition salts and base addition salts.
- Specific examples of the acid addition salt include hydrochlorides, hydrobromides, hydroiodides, sulfates, nitrates, acid addition salts with inorganic acids such as phosphates; benzoates, methane Acid addition salts with organic acids such as sulfonates, ethane sulfonates, benzene sulfonates, p-toluene sulfonates, maleates, fumarates, tartrates, citrates, acetates, etc. .
- base addition salt specifically, metal salts such as sodium salt, potassium salt, lithium salt, calcium salt and magnesium salt; salts with amines such as ammonia, trimethylamine, triethylamine, pyridine, collidine, lutidine and the like; A base addition salt with an organic base such as lysine, arginine, cinchonine, cinchonidine and the like can be mentioned.
- the shape, size, etc. of pemafibrate or a salt thereof or a solvate thereof are not particularly limited, but when the average particle size of primary particles is measured according to the particle size measurement method by the 17th revision Japanese Pharmacopoeia laser diffraction method,
- Each of d50 and d90 is preferably as follows.
- the d50 is preferably 100 ⁇ m or less, more preferably 50 ⁇ m or less, still more preferably 20 ⁇ m or less, and particularly preferably 1 to 20 ⁇ m.
- the d90 200 ⁇ m or less is preferable, 135 ⁇ m or less is more preferable, 80 ⁇ m or less is more preferable, and 1 to 80 ⁇ m is particularly preferable.
- Pemafibrate or a salt thereof or a solvate thereof is a known compound and can be produced, for example, by the method disclosed in Patent Document 1, Non-patent Document 1, US Patent No. 7,109,226. .
- crystals of pemafibrate which can be produced by the method described in Non-Patent Document 1 (preferably, when measured according to the 17th revision Japanese Pharmacopoeia melting point measurement method 1), particularly 95 to 101 ° C., particularly Preferably, crystals having a melting point of 97 to 100 ° C. are used.
- the contents of these documents are incorporated herein by reference.
- pemafibrate or a salt thereof or a solvate thereof in the pharmaceutical composition is not particularly limited, and is appropriately determined depending on the disease to be applied, the type of preparation, the sex of the user, the age, the condition, etc. be able to.
- pemafibrate or a salt thereof or a solvate thereof in terms of the free form of pemafibrate is preferably 0.05 to 0.8 mg, more preferably 0.075 to 0.6 mg, particularly preferably Can contain an amount that can be taken 0.1 to 0.4 mg.
- the content of pemafibrate or a salt thereof or a solvate thereof in the pharmaceutical composition is preferably 0.01 to 5% by mass in terms of free mass of pemafibrate based on the total mass of the pharmaceutical composition. And more preferably 0.025 to 1% by mass, and particularly preferably 0.05 to 0.5% by mass. According to the present invention, even when Pemafibrate or a salt thereof or a solvate thereof has such a low content, good content uniformity can be obtained.
- the “disaccharide” is selected from the group consisting of disaccharides themselves and those wherein all or part of the hydroxy groups of the disaccharides are substituted with halogen atoms such as chlorine atoms, and solvates thereof Means more than species.
- the solvate is not particularly limited, and specific examples thereof include hydrate and the like.
- the kind of monosaccharide which comprises a disaccharide is not specifically limited, For example, pentoses, such as arabinose and xylose; Hexose, such as glucose, galactose, fructose, mannose, altrose, rhamnose, etc. are mentioned.
- disaccharides include sucrose (sucrose), lactulose, lactose (lactose), maltose, trehalose, cellobiose, cordibiose, nigerose, isomaltose, isotreoseose, neotrehalose, sophorose, laminaribiose, Genthiobiose, tulanose, maltulose, palatinose, gentiobiulose, mannobiose, melibiose, melibiulose, neolactose, neolactose, galactosucrose, silabiose, rutinose, rutinulose, bicyanose, xylobiose, primevirose, sucralose, etc. Or a combination of two or more.
- the disaccharide is preferably at least one member selected from the group consisting of sucrose, lactose, maltose, trehalose, palatinose and sucralose, and solvates thereof from the viewpoint of the action to improve the content uniformity, sucrose, lactose, One or more selected from the group consisting of trehalose and sucralose and their hydrates is more preferable, and one or more selected from the group consisting of lactose and its hydrate is more preferable, lactose / crystalline cellulose spherical granules, lactose water One or more selected from the group consisting of hydrates, lactose granules and anhydrous lactose are particularly preferred.
- disaccharide one which is solid at normal temperature (a temperature of 15 to 25 ° C.) is preferable.
- these disaccharides are all known components, and may be produced by known methods, or commercially available products may be used.
- commercially available products for example, Nonparel-105 (Freund Industry Co., Ltd.), lactose hydrate (San-Ei Gen F.F.I.
- Lactose G (Freund Industry Co., Ltd.), Lactopress anhydrous (Freund Industry Co., Ltd.) CBC Co., Ltd., eclipse crystal maltose (Nippon Food Chemical Co., Ltd.), Trehalose P (Asahi Kasei Co., Ltd.), Sucralose (San-Ei Gen F.F.I. Co., Ltd.), Pharmatose 200 M (DFE pharma), etc. Can be mentioned.
- the content of the disaccharide in the pharmaceutical composition is not particularly limited, and can be appropriately determined and determined according to the type of preparation, sex of the user, age, symptoms and the like, but the aspect of improving the content uniformity Therefore, the total amount of disaccharides is preferably 1 to 99% by mass, more preferably 3 to 95% by mass, still more preferably 5 to 90% by mass, based on the total mass of the pharmaceutical composition. Preferably, it is 7 to 85% by mass.
- the content is preferably 2 to 98% by mass, more preferably 4 to 93% by mass, and particularly preferably 8 to 80% by mass.
- the content ratio by mass of pemafibrate or a salt thereof or a solvate thereof and a disaccharide in the pharmaceutical composition is not particularly limited, but from the viewpoint of improving the content uniformity, 1 mass part in terms of free form of pemafibrate
- the total amount of disaccharides is preferably 10 to 1750 parts by mass, more preferably 50 to 1500 parts by mass, still more preferably 80 to 1200 parts by mass, and still more preferably 100 to 900 parts by mass. Is particularly preferred.
- the content ratio with the one or more selected from the group is not particularly limited, but from the viewpoint of the action to improve the content uniformity, a group consisting of lactose and a hydrate thereof relative to 1 part by mass in terms of free body of pemafibrate Is preferably contained in total of 30 to 1150 parts by mass, more preferably 50 to 1050 parts by mass, still more preferably 70 to 950 parts by mass, and still more preferably 120 to 850 parts by mass. It is particularly preferred to
- one further containing cellulose in addition to the components (A) and (B) is preferable.
- cellulose means one or more selected from the group consisting of cellulose and salts thereof.
- the type of salt is not particularly limited, and specific examples thereof include alkali metal salts such as sodium salts and potassium salts; salts with metals of Group 2 elements such as calcium salts and magnesium salts, and the like.
- the average degree of polymerization and properties (crystal form) of cellulose are not particularly limited, but the average degree of polymerization is preferably 50 to 10,000.
- the average degree of polymerization can be confirmed by conducting the test in accordance with the confirmation test (3) described in the section “Crystalline cellulose” of the 17th Amended Japanese Pharmacopoeia.
- Specific examples of such cellulose include crystalline cellulose, crystalline cellulose (fine particles), crystalline cellulose (grains), powdered cellulose, powdered cellulose (average degree of polymerization: 800 to 1100), etc. These may be used alone or in combination of two or more.
- these crystalline cellulose etc. shall refer to crystalline cellulose etc.
- celluloses which are described in the pharmaceutical additive dictionary 2016 (issued by Yakuhin Nipponsha Co., Ltd.). These celluloses are all known components, and may be produced by known methods, or commercially available products may be used. Examples of such commercially available products include Theorus PH-101 (Asahi Kasei Corporation), Celfia (San-Ei Gen F.F.I. Ltd.), ARBOCEL (Kimura Sangyo Co., Ltd.) and the like.
- the content of cellulose in the pharmaceutical composition is not particularly limited, and can be appropriately determined and determined according to the type of preparation, sex of the user, age, symptoms and the like, but from the viewpoint of improving the content uniformity.
- the total amount of cellulose is preferably 1 to 40% by mass, more preferably 3 to 35% by mass, and still more preferably 5 to 30% by mass, based on the total mass of the pharmaceutical composition. Particularly preferred is 8 to 25% by mass.
- the content ratio by mass of pemafibrate or a salt thereof or a solvate thereof and cellulose in the pharmaceutical composition is not particularly limited, but from the viewpoint of improving the content uniformity, it is 1 part by mass in terms of free substance of pemafibrate
- the total amount of cellulose is preferably 5 to 5,000 parts by mass, more preferably 30 to 3,500 parts by mass, and particularly preferably 60 to 2,000 parts by mass.
- the dosage form of the “pharmaceutical composition” is not particularly limited, and may be a solid, semi-solid or liquid preparation, and can be selected according to the purpose of use and the like.
- the dosage form of the pharmaceutical composition includes, for example, the dosage form described in the General Regulations of the Japanese Pharmacopoeia, 17th Edition.
- dosage forms for oral administration include tablets (for example, normal tablets, orally disintegrating tablets, chewable tablets, effervescent tablets, dispersed tablets, dissolved tablets, etc.), capsules, granules (for example, Solid preparations such as effervescent granules etc., powders, pills etc. semi-solid preparations such as oral jelly etc.
- oral liquids eg including elixirs, suspensions, emulsions, limonade etc
- dosage forms for parenteral administration include injections, inhalants, eye drops, ear drops, nasal drops, suppositories, external solid preparations, external solutions, sprays, ointments, creams, gels , Patch and the like.
- the pharmaceutical composition is preferably a solid preparation in terms of ease of administration and ease of production.
- a solid preparation basically has a solid component at normal temperature (a temperature of 15 to 25 ° C.). Since many components are used for production, mixing / dispersion among the components tends to be nonuniform, and deterioration of content uniformity tends to be particularly problematic. However, according to the present invention, even in the case of a solid preparation, it has an excellent effect that the content uniformity is good.
- a solid preparation for oral administration is preferable, a tablet, a capsule, a granule, a powder, a pill is more preferable, and a tablet is particularly preferable. Further, as the solid preparation, a solid preparation containing a mixture containing the components (A) and (B) is preferable, and a solid preparation containing a mixture containing the components (A) to (C) is more preferable.
- a pharmaceutically acceptable carrier may be added to the pharmaceutical composition of the present invention depending on the dosage form.
- formulation additives include, for example, excipients, disintegrants, binders, lubricants, plasticizers, film-forming agents, powders, poorly water-soluble polymer substances, antioxidants, flavors, sweeteners, etc.
- specific examples of these pharmaceutical additives include those listed in Pharmaceutical Additive Dictionary 2016 (issued by Yakuhin Nipponsha Co., Ltd.), Handbook of Pharmaceutical Excipients, Seventh Edition (issued by Pharmaceutical Press), etc. It may be used.
- excipient specifically, for example, aluminum silicate, anhydrous sodium sulfate, sodium chloride, light anhydrous silicic acid, heavy anhydrous silicic acid, calcium sulfate, calcium monohydrogen phosphate, sodium hydrogen phosphate, phosphoric acid
- Inorganic excipients such as potassium dihydrogen, calcium dihydrogen phosphate and sodium dihydrogen phosphate; starches (wheat starch, rice starch, corn starch, partially pregelatinized starch etc.), fructose, caramel, abaum, xylitol, paraffin ,
- Organic excipients such as glucose, pullulan, polyoxyethylene hydrogenated castor oil, maltitol, erythritol, erythritol, sorbitol, mannitol, lactitol, aminoalkyl methacrylate copolymer E, polyvinylacetal diethylaminoacetate, calcium citrate and the like It is. These can be
- disintegrant specifically, for example, super disintegrants such as sodium carboxymethyl starch, croscarmellose sodium, crospovidone, carmellose, carmellose calcium, starch, sucrose fatty acid ester, gelatin, dextrin, dehydroacetic acid and the like Salt, povidone, polyoxyethylene hydrogenated castor oil 60 and the like can be mentioned. These can be used 1 type or in combination of 2 or more types. Among these disintegrants, sodium carboxymethyl starch and croscarmellose sodium are preferred.
- the binder include fats and oils such as hydrogenated beef tallow oil, hydrogenated oil, hydrogenated vegetable oil, hydrogenated soybean oil, carnauba wax, white beeswax, beeswax and bee wax, methylcellulose, hydroxypropyl cellulose, hypromellose, carme Loin sodium, starch (wheat starch, rice starch, corn starch, partially pregelatinized starch etc.), dextrin, pullulan, gum arabic, agarten, gelatin, tragacanth, sodium alginate, povidone, polyvinyl alcohol, aminoalkyl methacrylate copolymer E, polyvinyl acetal Diethyl amino acetate etc. are mentioned. These can be used 1 type or in combination of 2 or more types. Among these binders, carnauba wax, hydroxypropyl cellulose, hypromellose, povidone and aminoalkyl methacrylate copolymer E are preferred.
- the lubricant examples include calcium stearate, magnesium stearate, sodium stearyl fumarate, sucrose fatty acid ester and the like. These can be used 1 type or in combination of 2 or more types. Among these lubricants, calcium stearate, magnesium stearate and sodium stearyl fumarate are preferred.
- plasticizer examples include triethyl citrate, glycerin, sesame oil, sorbitol, castor oil, polysorbate 80 (polyoxyethylene (20) sorbitan oleate) and the like. These can be used 1 type or in combination of 2 or more types. Among these plasticizers, triethyl citrate, glycerin and sorbitol are preferred.
- the film-forming agent examples include alkylcelluloses such as methylcellulose and ethylcellulose; alginic acid such as sodium alginate or a salt thereof; carrageenan; carboxymethylcellulose sodium, carboxymethylcellulose calcium, carboxymethylcellulose potassium, carboxymethylcellulose, carboxymethylethylcellulose and the like Carboxyalkyl celluloses; xanthan gum; hydroxyalkyl celluloses such as hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose (hydroxypropyl methyl cellulose); hydroxyalkyl cellulose phthalates such as hydroxypropyl methylcellulose phthalate; pullulan; polyvinyl acetate Polyvinyl acetate phthalate, polyvinyl pyrrolidone, and the like. These can be used 1 type or in combination of 2 or more types. Among these film forming agents, alkyl cellulose and hydroxyalkyl cellulose are preferred.
- the powder examples include organic powder or inorganic powder such as talc, titanium oxide, yellow ferric oxide, ferric oxide and legal pigments. These can be used 1 type or in combination of 2 or more types. Among these powders, titanium oxide, yellow ferric oxide, ferric oxide and legal pigments are preferred.
- the poorly water-soluble polymer substance include carboxyvinyl polymer, aminoalkyl methacrylate copolymer and the like. These can be used 1 type or in combination of 2 or more types.
- Specific examples of the antioxidant include ascorbic acid, sodium bisulfite, sodium sulfite, sodium edetate, erythorbic acid, tocopherol acetate, dibutyl hydroxytoluene, natural vitamin E, tocopherol, butyl hydroxyanisole and the like. These can be used 1 type or in combination of 2 or more types.
- flavoring agent examples include limonene, pinene, camphene, cymen, cineole, citronellol, geraniol, nerol, linalool, linalol, menthol, terpineol, rosinol, borneol, isoborneol, menthol, camphor, eugenol, synseilanol, etc.
- Essential oils containing terpenes of the following; and acidulants such as ascorbic acid, tartaric acid, citric acid, malic acid and salts thereof. These can be used 1 type or in combination of 2 or more types.
- sweetening agents include aspartame, stevia, glycyrrhizinic acid, thaumatin, acesulfame potassium, saccharin, saccharin sodium and the like, and one or more of these can be used in combination.
- composition of the present invention among the above-mentioned pharmaceutically acceptable carriers, croscarmellose sodium, magnesium stearate, titanium oxide, triethyl citrate, hypromellose, hydroxypropyl cellulose, light anhydrous silicic acid and carnauba wax are preferable. It is preferable to contain one or more selected from the group consisting of
- the pharmaceutical composition of the present invention can be manufactured according to known methods depending on its dosage form.
- the pharmaceutical composition when it is a solid preparation, it can be produced by appropriately combining unit operations such as grinding, mixing, granulation, drying, sizing, classification, filling, tableting, and coating.
- a method comprising the step of mixing the component (A) and the component (B) is preferable, and a method comprising the step of mixing the components (A) to (C) is more preferable.
- the dosage form of the pharmaceutical composition is a granular preparation such as granules, powders, pills, etc.
- the component (C) ) and other formulation additives such as excipients, binders, disintegrants, and lubricants, and after these components are mixed, extrusion granulation, tumbling granulation, agitation granulation, fluidized bed granulation Granules are obtained by granulation using known granulation methods such as spray granulation, melt granulation, crushing granulation, etc. to obtain granulated products, and further, they can be manufactured by classification, sizing, etc. as required.
- the obtained granulated material can also be coat
- the dosage form of the pharmaceutical composition is a tablet, in addition to the component (A) and the component (B), if necessary, in addition to the component (C), excipients, binders, disintegrants, lubricants These ingredients are mixed to obtain a mixture using an appropriate formulation additive such as an agent, and this is directly compressed (tablet) (direct powder compression method), or the above-mentioned granulated product is used if necessary.
- tablette It can be manufactured by classification (sorting), sizing and the like followed by compression (tablet) (semi-dry granular compression method, dry granular compression method, wet granular compression method, etc.).
- tablette can also be coated with a coating agent etc. by a well-known method.
- the dosage form of the pharmaceutical composition is a capsule, the above-mentioned granulated product or compressed product may be filled in the capsule.
- the disease to which the pharmaceutical composition of the present invention is applied is not limited in any way, and can be widely used for the prevention or treatment of a disease known or to be found at the present to be effective for administration of pemafibrate.
- pemafibrate or a salt thereof or a solvate thereof has excellent PPAR ⁇ agonist activity, and has actions such as lowering of plasma triglyceride level and increase of HDL cholesterol. Therefore, the pharmaceutical composition of the present invention is preferably used for the prevention and / or treatment of dyslipidemia (hyperlipidemia, more specifically, for example, primary hyperlipidemia, secondary hyperlipidemia, etc.)
- dyslipidemia hyperlipidemia, more specifically, for example, primary hyperlipidemia, secondary hyperlipidemia, etc.
- it can be used more preferably as an agent for preventing and / or treating hypertriglyceridemia.
- pemafibrate or a salt thereof or a solvate thereof is useful for the prevention or treatment of NAFLD (non-alcoholic fatty liver disease). Therefore, the pharmaceutical composition of the present invention can also be used as an agent for preventing and / or treating NAFLD (more preferably, NASH (nonalcoholic steatohepatitis)). Furthermore, pemafibrate or a salt thereof or a solvate thereof may be used as a therapeutic agent or the like for primary biliary cirrhosis.
- the route of administration of the pharmaceutical composition is not particularly limited, and can be appropriately determined and determined according to the disease to be applied, type of preparation, sex of the user, age, symptoms, etc., but from the viewpoint of ease of administration. , Oral administration is preferred.
- the pharmaceutical composition can be divided into about 1 to 4 times a day and taken before meals, between meals, after meals, before going to bed, and the like.
- Component (B) is sucrose (sucrose), lactulose, lactose (lactose), maltose, trehalose, cellobiose, kojibiose, nigerose, isomaltose, isotrehalose, neotrehalose, sophorose, laminaribiose, gentiobiose , Tulanose, maltulose, palatinose, gentiobiulose, mannobiose, melibiose, melibiulose, neolactose, galactosucrose, silabiose, rutinose, rutinulose, bicyanose, xylobiose, primevevelose and sucralose, and solvates thereof 1
- the pharmaceutical composition according to [1-1] which is a species or more.
- [1-7] dyslipidemia hyperlipidemia, more specifically, for example, primary hyperlipidemia, secondary hyperlipidemia, etc.
- NAFLD more preferably, NASH (nonalcoholic fatty non-alcoholic)
- Component (B) is sucrose (sucrose), lactulose, lactose (lactose), maltose, trehalose, cellobiose, cordiose, nigerose, isomaltose, isotrehalose, neotrehalose, sophorose, laminaribiose, gentiobiose , Tulanose, maltulose, palatinose, gentiobiulose, mannobiose, melibiose, melibiulose, neolactose, galactosucrose, silabiose, rutinose,
- the pharmaceutical composition is preferably a dyslipidemia (hyperlipidemia, more specifically, for example, primary hyperlipidemia, secondary hyperlipidemia, etc.), NAFLD (more preferably NASH (more preferably The method according to any one of [2-1] to [2-6], which is an agent for the prophylaxis and / or treatment of a disease selected from nonalcoholic steatohepatitis) and primary biliary cirrhosis.
- NAFLD more preferably NASH
- the method according to any one of [2-1] to [2-6] which is an agent for the prophylaxis and / or treatment of a disease selected from nonalcoholic steatohepatitis) and primary biliary cirrhosis.
- the dosage form of the pharmaceutical composition is a tablet, a capsule, a granule, a powder or a pill.
- Example 1 Content Uniformity Evaluation Test
- Tablets were manufactured so that the amount per tablet of each component described in Table 1 would be the amount (mg) described in Table 1.
- the specific procedure is shown below.
- Example 1 Pemafibrate, lactose hydrate, croscarmellose sodium and hydroxypropyl cellulose are mixed for 5 minutes, then purified water is added, the mixture is kneaded for 3 minutes, granulated, dried and then sized to obtain granules Obtained. After mixing magnesium stearate with the obtained granulated product, it was tableted to produce 10000 tablets of 120 mg per tablet.
- Example 2 In the same manner as in Example 1 except that a part of lactose hydrate was replaced by crystalline cellulose, 10,000 tablets of 120 mg per tablet were produced.
- Example 1 In the same manner as in Example 1 except that the total amount of lactose hydrate was replaced with crystalline cellulose, 10,000 tablets of 120 mg per tablet were produced.
- Ten tablets of each of the obtained tablets of each example or comparative example were randomly taken out, and one tablet at a time was used to measure the content of pemafibrate in the tablet according to the following method. That is, one tablet was put in water and crushed, and then acetonitrile was added to obtain a sample solution. The obtained sample solution was analyzed by an HPLC apparatus, and the peak area derived from pemafibrate was measured. Then, the content of pemafibrate for each tablet was determined by comparing the peak area derived from pemafibrate in the obtained sample solution with the peak area of a standard solution of pemafibrate having a known concentration.
- the relative standard deviation (RSD) (%) of the content of pemafibrate in the tablet was calculated from the measured value of the content of pemafibrate for each tablet obtained, in accordance with the 17th Amended Japanese Pharmacopoeia Content Uniformity Test. It was taken as an index of variation (degree of uniformity) of pemafibrate content in tablets. The obtained results are shown in Table 1.
- Example 1 As shown in the results shown in Table 1, when the lactose hydrate as a disaccharide is contained (Examples 1 and 2), the relative standard deviations are all smaller compared to Comparative Example 1 containing no disaccharide, It was found that the uniformity of the pemafibrate content per tablet was good. In particular, in addition to lactose hydrate, Example 2 further containing crystalline cellulose had a smaller relative standard deviation, and the uniformity of the pemafibrate content per tablet was particularly good.
- a tablet containing the ingredients and amount (mg) described in Table 2 per tablet can be produced by a wet granular compression method according to a conventional method.
- Tablets containing the ingredients and amounts (mg) described in Table 3 per tablet can be produced by direct powder compression according to a conventional method.
- a pharmaceutical composition excellent in homogeneity which contains pemafibrate exhibiting effects such as a decrease in plasma triglyceride concentration and an increase in HDL cholesterol, it can be used, for example, in the pharmaceutical industry.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
そして、ペマフィブラート若しくはその塩又はそれらの溶媒和物については、上記のような薬理効果を示すということが報告されているのみであり、医薬組成物とすることについてはこれまでに具体的に検討がされておらず、医薬組成物の均質性等の製造性についてはこれまでに全く報告されていなかった。
このような背景の下、ペマフィブラート若しくはその塩又はそれらの溶媒和物を含有する医薬組成物を開発するため、本発明者らは、まずは医薬組成物を実際に製造してみた。しかるところ、医薬組成物ごとにペマフィブラートの含量にばらつきが生じ、医薬組成物中のペマフィブラートの含量の均質性(含量均一性)に問題が生じることが判明した。医薬組成物ごとにペマフィブラートの含量が大きく異なれば、医薬組成物間で有効性・安全性にばらつきが生じることにもなりかねない。
したがって、本発明の課題は、ペマフィブラート若しくはその塩又はそれらの溶媒和物を含有し、均質性に優れる医薬組成物を提供することにある。
(A)ペマフィブラート若しくはその塩又はそれらの溶媒和物;
(B)二糖類;
を含有する、医薬組成物を提供するものである。
本明細書において「ペマフィブラート若しくはその塩又はそれらの溶媒和物」には、ペマフィブラート(化学名:(2R)-2-[3-({1,3-ベンゾオキサゾール-2-イル[3-(4-メトキシフェノキシ)プロピル]アミノ}メチル)フェノキシ]ブタン酸((2R)-2-[3-([1,3-Benzoxazol-2-yl[3-(4-methoxyphenoxy)propyl]amino]methyl)phenoxy]butanoic acid)、国際一般名:Pemafibrate)そのもののほか、ペマフィブラートの薬学上許容される塩、さらにはペマフィブラートやその薬学上許容される塩と、水やアルコール(例えば、エタノール)等との溶媒和物も含まれる。薬学上許容される塩としては特に限定されないが、例えば、酸付加塩や塩基付加塩等が挙げられる。酸付加塩としては、具体的には、塩酸塩、臭化水素酸塩、ヨウ化水素酸塩、硫酸塩、硝酸塩、リン酸塩のような無機酸との酸付加塩;安息香酸塩、メタンスルホン酸塩、エタンスルホン酸塩、ベンゼンスルホン酸塩、p-トルエンスルホン酸塩、マレイン酸塩、フマル酸塩、酒石酸塩、クエン酸塩、酢酸塩等の有機酸との酸付加塩が挙げられる。また、塩基付加塩としては、具体的には、ナトリウム塩、カリウム塩、リチウム塩、カルシウム塩、マグネシウム塩等の金属塩;アンモニア、トリメチルアミン、トリエチルアミン、ピリジン、コリジン、ルチジン等のアミンとの塩;リシン、アルギニン、シンコニン、シンコニジン等の有機塩基との塩基付加塩等が挙げられる。
d50:100μm以下であるのが好ましく、50μm以下であるのがより好ましく、20μm以下がさらにより好ましく、1~20μmであるのが特に好ましい。
d90:200μm以下であるのが好ましく、135μm以下であるのがより好ましく、80μm以下であるのがさらに好ましく、1~80μmであるのが特に好ましい。
医薬組成物におけるペマフィブラート若しくはその塩又はそれらの溶媒和物の含有量としては、医薬組成物全質量に対して、ペマフィブラートのフリー体換算で、0.01~5質量%であるのが好ましく、0.025~1質量%であるのがより好ましく、0.05~0.5質量%であるのが特に好ましい。本発明によれば、ペマフィブラート若しくはその塩又はそれらの溶媒和物がこのような低含量の場合であっても、良好な含量均一性が得られる。
本明細書において「二糖類」とは、二糖そのもの及び二糖のヒドロキシ基の全部又は一部が塩素原子等のハロゲン原子に置換されたもの並びにそれらの溶媒和物よりなる群から選ばれる1種以上を意味する。ここで、溶媒和物としては、特に限定されず、具体的には例えば、水和物等が挙げられる。なお、二糖を構成する単糖の種類は特に限定されず、例えば、アラビノース、キシロース等のペントース;グルコース、ガラクトース、フルクトース、マンノース、アルトロース、ラムノース等のヘキソースなどが挙げられる。
こうした二糖類としては、具体的には例えば、ショ糖(スクロース)、ラクツロース、乳糖(ラクトース)、マルトース、トレハロース、セルビオース、コージビオース、ニゲロース、イソマルトース、イソトレハロース、ネオトレハロース、ソホロース、ラミナリビオース、ゲンチオビオース、ツラノース、マルツロース、パラチノース、ゲンチオビウロース、マンノビオース、メリビオース、メリビウロース、ネオラクトース、ガラクトスクロース、シラビオース、ルチノース、ルチヌロース、ビシアノース、キシロビオース、プリメベロース、スクラロースなどが挙げられ、これらのうち1種を単独で用いても2種以上を組み合わせて用いてもよい。
なお、これらの二糖類はいずれも公知の成分であり、公知の方法により製造しても良く、また、市販品を使用しても良い。なお、こうした市販品としては例えば、ノンパレル-105(フロイント産業(株))、乳糖水和物(三栄源エフ・エフ・アイ(株))、乳糖G(フロイント産業(株))、Lactopress anhydrous(CBC(株))、日食結晶マルトース(日本食品化工(株))、トレハロースP(旭化成(株))、スクラロース(三栄源エフ・エフ・アイ(株))、Pharmatose 200M(DFE pharma社)等が挙げられる。
本発明の医薬組成物としては、成分(A)及び(B)に加えて、さらにセルロースを含有するものが好ましい。二糖類とセルロースを組み合わせて含有せしめることにより、ペマフィブラートの含量均一性がより良好となる。
本明細書において「セルロース」とは、セルロース及びその塩よりなる群から選ばれる1種以上を意味する。セルロースにおいて、塩の種類は特に限定されず、具体的には例えば、ナトリウム塩、カリウム塩等のアルカリ金属塩;カルシウム塩、マグネシウム塩等の第2族元素の金属との塩等が挙げられる。また、セルロースの平均重合度や性状(結晶形)等は特に限定されないが、平均重合度は好ましくは50~10000である。なお、ここで、平均重合度は、第十七改正日本薬局方 「結晶セルロース」の項に記載の確認試験(3)に準じて試験を行うことにより確認できる。
こうしたセルロースとしては、具体的には例えば、結晶セルロース、結晶セルロース(微粒子)、結晶セルロース(粒)、粉末セルロース、粉末セルロース(平均重合度:800~1100)等が挙げられ、これらのうち1種を単独で用いても2種以上を組み合わせて用いてもよい。なお、これら結晶セルロース等は、医薬品添加物辞典2016(株式会社薬事日報社発行)に記載の結晶セルロース等をいうものとする。
なお、これらのセルロースはいずれも公知の成分であり、公知の方法により製造しても良く、また、市販品を使用しても良い。なお、こうした市販品としては例えば、セオラス PH-101(旭化成(株))、セルフィア(三栄源エフ・エフ・アイ(株))、ARBOCEL(木村産業(株))等が挙げられる。
固形製剤としては、経口投与用固形製剤が好ましく、錠剤、カプセル剤、顆粒剤、散剤、丸剤がより好ましく、錠剤が特に好ましい。また、固形製剤としては、成分(A)及び(B)を含む混合物を含有する固形製剤が好ましく、成分(A)~(C)を含む混合物を含有する固形製剤がより好ましい。
これら賦形剤の中では、軽質無水ケイ酸、マンニトールが好ましい。
これら崩壊剤の中では、カルボキシメチルスターチナトリウム、クロスカルメロースナトリウムが好ましい。
これら結合剤の中では、カルナウバロウ、ヒドロキシプロピルセルロース、ヒプロメロース、ポビドン、アミノアルキルメタクリレートコポリマーEが好ましい。
これら滑沢剤の中では、ステアリン酸カルシウム、ステアリン酸マグネシウム、フマル酸ステアリルナトリウムが好ましい。
これら可塑剤の中では、クエン酸トリエチル、グリセリン、ソルビトールが好ましい。
これらフィルム形成剤の中では、アルキルセルロース、ヒドロキシアルキルセルロースが好ましい。
これら粉体の中では、酸化チタン、黄色三二酸化鉄、三二酸化鉄、法定色素が好ましい。
抗酸化剤としては、具体的には例えば、アスコルビン酸、亜硫酸水素ナトリウム、亜硫酸ナトリウム、エデト酸ナトリウム、エリソルビン酸、酢酸トコフェロール、ジブチルヒドロキシトルエン、天然ビタミンE、トコフェロール、ブチルヒドロキシアニソール等が挙げられる。これらは、1種又は2種以上を組み合わせて使用することができる。
例えば、医薬組成物が固形製剤である場合には、粉砕、混合、造粒、乾燥、整粒、分級、充填、打錠、コーティング等の単位操作を適宜組み合わせることにより製造することができるが、その製造方法としては、成分(A)と成分(B)とを混合する工程を含む方法が好ましく、成分(A)~(C)を混合する工程を含む方法がより好ましい。
より具体的には例えば、医薬組成物の剤形が顆粒剤、散剤、丸剤等の粒状の製剤の場合、成分(A)、成分(B)に加えて、必要に応じて、成分(C)の他、賦形剤や結合剤、崩壊剤、滑沢剤等の製剤添加物を用い、これらの成分を混合した後、押出造粒、転動造粒、攪拌造粒、流動層造粒、噴霧造粒、溶融造粒、破砕造粒等の公知の造粒方法により造粒して造粒物を得、さらに必要に応じて分級、整粒等することで製造することができる。なお、得られた造粒物は、公知の方法によりコーティング剤等で被覆することもできる。
また、医薬組成物の剤形が錠剤の場合、成分(A)、成分(B)に加えて、必要に応じて、成分(C)の他、賦形剤や結合剤、崩壊剤、滑沢剤等の適当な製剤添加物を用い、これらの成分を混合して混合物を得、これを直接圧縮(打錠)すること(直接粉末圧縮法)や、上記の造粒物を必要に応じて分級、整粒等したあと圧縮(打錠)すること(半乾式顆粒圧縮法、乾式顆粒圧縮法、湿式顆粒圧縮法など)により製造することができる。なお、得られた圧縮物(錠剤)は、公知の方法によりコーティング剤等で被覆することもできる。
さらに、医薬組成物の剤形がカプセル剤の場合、上記の造粒物や圧縮物を、カプセルに充填すればよい。
例えば、ペマフィブラート若しくはその塩又はそれらの溶媒和物は優れたPPARαアゴニスト活性を有し、血漿トリグリセライド濃度の低下やHDLコレステロールの増加等の作用を有する。従って、本発明の医薬組成物は、好適には、脂質異常症(高脂血症、より詳細には例えば、原発性高脂血症、続発性高脂血症等)の予防及び/又は治療剤として、さらに好適には高トリグリセライド血症の予防及び/又は治療剤等として使用できる。
また、ペマフィブラート若しくはその塩又はそれらの溶媒和物は、NAFLD(非アルコール性脂肪性肝疾患)の予防又は治療に有用である。従って、本発明の医薬組成物は、NAFLD(より好適には、NASH(非アルコール性脂肪性肝炎))の予防及び/又は治療剤等としても使用できる。
さらに、ペマフィブラート若しくはその塩又はそれらの溶媒和物は、原発性胆汁性肝硬変の治療剤等として使用してもよい。
[1-1] 次の成分(A)及び(B):
(A)ペマフィブラート若しくはその塩又はそれらの溶媒和物;
(B)二糖類;
を含有する、医薬組成物。
[1-2] 成分(B)が、ショ糖(スクロース)、ラクツロース、乳糖(ラクトース)、マルトース、トレハロース、セルビオース、コージビオース、ニゲロース、イソマルトース、イソトレハロース、ネオトレハロース、ソホロース、ラミナリビオース、ゲンチオビオース、ツラノース、マルツロース、パラチノース、ゲンチオビウロース、マンノビオース、メリビオース、メリビウロース、ネオラクトース、ガラクトスクロース、シラビオース、ルチノース、ルチヌロース、ビシアノース、キシロビオース、プリメベロース及びスクラロース並びにそれらの溶媒和物よりなる群から選ばれる1種以上である、[1-1]記載の医薬組成物。
[1-3] 成分(B)が、ショ糖、乳糖、マルトース、トレハロース、パラチノース及びスクラロース並びにそれらの溶媒和物よりなる群から選ばれる1種以上である、[1-1]記載の医薬組成物。
[1-4] 成分(B)が、ショ糖、乳糖、トレハロース及びスクラロース並びにそれらの水和物よりなる群から選ばれる1種以上である、[1-1]記載の医薬組成物。
[1-5] 成分(B)が、乳糖及びその水和物よりなる群から選ばれる1種以上である、[1-1]記載の医薬組成物。
[1-6] さらに、成分(C):
(C)セルロース;
を含有する、[1-1]~[1-5]のいずれか記載の医薬組成物。
[1-8] 固形製剤である、[1-1]~[1-7]のいずれか記載の医薬組成物。
[1-9] 剤形が、錠剤、カプセル剤、顆粒剤、散剤又は丸剤である、[1-1]~[1-8]のいずれか記載の医薬組成物。
(B)二糖類;
を含有せしめる工程を含む、医薬組成物中のペマフィブラート若しくはその塩又はそれらの溶媒和物の含量均一性の改善方法。
[2-2] 成分(B)が、ショ糖(スクロース)、ラクツロース、乳糖(ラクトース)、マルトース、トレハロース、セルビオース、コージビオース、ニゲロース、イソマルトース、イソトレハロース、ネオトレハロース、ソホロース、ラミナリビオース、ゲンチオビオース、ツラノース、マルツロース、パラチノース、ゲンチオビウロース、マンノビオース、メリビオース、メリビウロース、ネオラクトース、ガラクトスクロース、シラビオース、ルチノース、ルチヌロース、ビシアノース、キシロビオース、プリメベロース及びスクラロース並びにそれらの溶媒和物よりなる群から選ばれる1種以上である、[2-1]記載の方法。
[2-3] 成分(B)が、ショ糖、乳糖、マルトース、トレハロース、パラチノース及びスクラロース並びにそれらの溶媒和物よりなる群から選ばれる1種以上である、[2-1]記載の方法。
[2-4] 成分(B)が、ショ糖、乳糖、トレハロース及びスクラロース並びにそれらの水和物よりなる群から選ばれる1種以上である、[2-1]記載の方法。
[2-5] 成分(B)が、乳糖及びその水和物よりなる群から選ばれる1種以上である、[2-1]記載の方法。
[2-6] さらに、成分(C):
(C)セルロース;
を含有せしめる工程を含む、[2-1]~[2-5]のいずれか記載の方法。
[2-8] 医薬組成物が固形製剤である、[2-1]~[2-7]のいずれか記載の方法。
[2-9] 医薬組成物の剤形が、錠剤、カプセル剤、顆粒剤、散剤又は丸剤である、[2-1]~[2-8]のいずれか記載の方法。
なお、以下の試験例において、HPLCを用いた測定は、カラムとしてODSカラムを、検出器として紫外吸光光度計をそれぞれ用いて行った。
また、以下の試験例において使用したペマフィブラートについて、第十七改正日本薬局方 レーザー回折法による粒子径測定法に従って一次粒子の平均粒子径を測定した結果、d50は100μm以下であり、d90は200μm以下であった。
医薬組成物中のペマフィブラート含量の均一性を評価するため、以下の試験を実施した。
すなわち、表1記載の各成分の1錠当りの分量が、表1記載の分量(mg)となるように、錠剤を製造した。具体的な手順を以下に示す。
(実施例1)
ペマフィブラート、乳糖水和物、クロスカルメロースナトリウム及びヒドロキシプロピルセルロースを5分間混合した後、精製水を加えて3分間練合し、造粒し、乾燥した後、整粒して造粒物を得た。得られた造粒物にステアリン酸マグネシウムを混合した後、打錠し、1錠当り120mgの錠剤10000錠を製造した。
(実施例2)
乳糖水和物の一部を結晶セルロースに置き換えたほかは実施例1と同様の方法により、1錠当り120mgの錠剤10000錠を製造した。
(比較例1)
乳糖水和物の全量を結晶セルロースに置き換えたほかは実施例1と同様の方法により、1錠当り120mgの錠剤10000錠を製造した。
すなわち、錠剤1錠を水に入れて破砕し、その後アセトニトリルを加えて試料溶液を得た。得られた試料溶液をHPLC装置にて分析し、ペマフィブラート由来のピーク面積を測定した。そして、得られた試料溶液中のペマフィブラート由来のピーク面積を、濃度既知のペマフィブラートの標準液のピーク面積と比較することによって、錠剤1錠ごとのペマフィブラートの含量を測定した。
得られた結果を表1に示す。
表2に記載の成分及び分量(mg)を1錠当りに含有する錠剤を、常法により湿式顆粒圧縮法にて製造できる。
表3に記載の成分及び分量(mg)を1錠当りに含有する錠剤を、常法により直接粉末圧縮法にて製造できる。
Claims (7)
- 次の成分(A)及び(B):
(A)ペマフィブラート若しくはその塩又はそれらの溶媒和物;
(B)二糖類;
を含有する、医薬組成物。 - 前記成分(B)が、ショ糖、ラクツロース、乳糖、マルトース、トレハロース、セルビオース、コージビオース、ニゲロース、イソマルトース、イソトレハロース、ネオトレハロース、ソホロース、ラミナリビオース、ゲンチオビオース、ツラノース、マルツロース、パラチノース、ゲンチオビウロース、マンノビオース、メリビオース、メリビウロース、ネオラクトース、ガラクトスクロース、シラビオース、ルチノース、ルチヌロース、ビシアノース、キシロビオース、プリメベロース及びスクラロース並びにそれらの溶媒和物よりなる群から選ばれる1種以上である、請求項1記載の医薬組成物。
- 前記成分(B)が、ショ糖、乳糖、マルトース、トレハロース、パラチノース及びスクラロース並びにそれらの溶媒和物よりなる群から選ばれる1種以上である、請求項1又は2記載の医薬組成物。
- さらに、成分(C):
(C)セルロース;
を含有する、請求項1~3のいずれか1項記載の医薬組成物。 - 固形製剤である、請求項1~4のいずれか1項記載の医薬組成物。
- 剤形が、錠剤、カプセル剤、顆粒剤、散剤又は丸剤である、請求項1~5のいずれか1項記載の医薬組成物。
- ペマフィブラート若しくはその塩又はそれらの溶媒和物を含有する医薬組成物に、二糖類を含有せしめる工程を含む、医薬組成物中のペマフィブラート若しくはその塩又はそれらの溶媒和物の含量均一性の改善方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/627,141 US11406621B2 (en) | 2017-06-30 | 2018-06-29 | Pharmaceutical composition |
JP2019527072A JP7104039B2 (ja) | 2017-06-30 | 2018-06-29 | 医薬組成物 |
CN201880043984.8A CN110831591A (zh) | 2017-06-30 | 2018-06-29 | 医药组合物 |
KR1020197038643A KR20200019903A (ko) | 2017-06-30 | 2018-06-29 | 의약 조성물 |
EP18825167.2A EP3646867A4 (en) | 2017-06-30 | 2018-06-29 | PHARMACEUTICAL COMPOSITION |
JP2022065280A JP2022082819A (ja) | 2017-06-30 | 2022-04-11 | 医薬組成物 |
JP2024026188A JP2024045760A (ja) | 2017-06-30 | 2024-02-26 | 医薬組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017128695 | 2017-06-30 | ||
JP2017-128695 | 2017-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019004449A1 true WO2019004449A1 (ja) | 2019-01-03 |
Family
ID=64742037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/024884 WO2019004449A1 (ja) | 2017-06-30 | 2018-06-29 | 医薬組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11406621B2 (ja) |
EP (1) | EP3646867A4 (ja) |
JP (4) | JP7104039B2 (ja) |
KR (1) | KR20200019903A (ja) |
CN (1) | CN110831591A (ja) |
WO (1) | WO2019004449A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112402381A (zh) * | 2020-11-19 | 2021-02-26 | 广州一品红制药有限公司 | 一种盐酸克林霉素棕榈酸酯颗粒组合物及其制备方法 |
US11406621B2 (en) | 2017-06-30 | 2022-08-09 | Kowa Company, Ltd. | Pharmaceutical composition |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7058763B2 (ja) * | 2018-12-27 | 2022-04-22 | 興和株式会社 | 医薬品 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005023777A1 (ja) | 2003-09-03 | 2005-03-17 | Kowa Co., Ltd. | Ppar活性化化合物及びこれを含有する医薬組成物 |
WO2014050134A1 (ja) * | 2012-09-27 | 2014-04-03 | 興和株式会社 | 脂質異常症治療剤 |
WO2015005365A1 (ja) | 2013-07-10 | 2015-01-15 | 興和株式会社 | 非アルコール性脂肪性肝疾患治療剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200601272B (en) * | 2003-09-03 | 2007-04-25 | Kowa Co | PPAR-activating compound and pharmaceutical composition containing same |
CH712649A1 (fr) * | 2016-07-05 | 2018-01-15 | Hemo Plus Sàrl | Centre de traitement pour des soins par hémodialyse. |
CN110831591A (zh) * | 2017-06-30 | 2020-02-21 | 兴和株式会社 | 医药组合物 |
-
2018
- 2018-06-29 CN CN201880043984.8A patent/CN110831591A/zh active Pending
- 2018-06-29 KR KR1020197038643A patent/KR20200019903A/ko not_active Application Discontinuation
- 2018-06-29 JP JP2019527072A patent/JP7104039B2/ja active Active
- 2018-06-29 EP EP18825167.2A patent/EP3646867A4/en active Pending
- 2018-06-29 WO PCT/JP2018/024884 patent/WO2019004449A1/ja active Application Filing
- 2018-06-29 US US16/627,141 patent/US11406621B2/en active Active
- 2018-07-02 JP JP2018126047A patent/JP2019011324A/ja active Pending
-
2022
- 2022-04-11 JP JP2022065280A patent/JP2022082819A/ja active Pending
-
2024
- 2024-02-26 JP JP2024026188A patent/JP2024045760A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005023777A1 (ja) | 2003-09-03 | 2005-03-17 | Kowa Co., Ltd. | Ppar活性化化合物及びこれを含有する医薬組成物 |
US7109226B2 (en) | 2003-09-03 | 2006-09-19 | Kowa Co., Ltd. | PPAR-activating compound and pharmaceutical composition comprising the compound |
WO2014050134A1 (ja) * | 2012-09-27 | 2014-04-03 | 興和株式会社 | 脂質異常症治療剤 |
WO2015005365A1 (ja) | 2013-07-10 | 2015-01-15 | 興和株式会社 | 非アルコール性脂肪性肝疾患治療剤 |
Non-Patent Citations (6)
Title |
---|
"Handbook of Pharmaceutical Excipients", PHARMACEUTICAL PRESS |
"Japanese Pharmaceutical Excipients Directory", 2016, YAKUJI NIPPO, LIMITED |
"The Japanese Pharmacopoeia", article "Laser Diffraction Measurement of Particle Size" |
ANONYMOUS: "Report on the deliberation results of parmodia tablets 0.1 mg", PMDA REPORT ON THE DELIBERATION RESULTS, 17 May 2017 (2017-05-17), pages 1 - 74, XP009518270, Retrieved from the Internet <URL:http://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf> * |
FRUCHART JC., CARDIOVASC DIABETOL, vol. 12, 2013, pages 82 |
YUKIYOSHI YAMAZAKI ET AL., SYNTHESIS, no. 7, 2008, pages 1017 - 1022 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11406621B2 (en) | 2017-06-30 | 2022-08-09 | Kowa Company, Ltd. | Pharmaceutical composition |
CN112402381A (zh) * | 2020-11-19 | 2021-02-26 | 广州一品红制药有限公司 | 一种盐酸克林霉素棕榈酸酯颗粒组合物及其制备方法 |
CN112402381B (zh) * | 2020-11-19 | 2023-02-28 | 广州一品红制药有限公司 | 一种盐酸克林霉素棕榈酸酯颗粒组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US20200155514A1 (en) | 2020-05-21 |
JP2022082819A (ja) | 2022-06-02 |
JP2024045760A (ja) | 2024-04-02 |
KR20200019903A (ko) | 2020-02-25 |
JPWO2019004449A1 (ja) | 2020-04-30 |
JP2019011324A (ja) | 2019-01-24 |
EP3646867A1 (en) | 2020-05-06 |
JP7104039B2 (ja) | 2022-07-20 |
EP3646867A4 (en) | 2021-03-24 |
CN110831591A (zh) | 2020-02-21 |
US11406621B2 (en) | 2022-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022082819A (ja) | 医薬組成物 | |
RU2600831C2 (ru) | Перорально вводимая фармацевтическая композиция | |
WO2019004451A1 (ja) | 医薬組成物 | |
JPWO2007097325A1 (ja) | リン酸オセルタミビル含有医薬組成物 | |
JP2024033011A (ja) | 医薬組成物 | |
JP2024014994A (ja) | 医薬組成物(3) | |
JP2024033012A (ja) | 医薬組成物 | |
JP7060878B2 (ja) | メトトレキサート含有フィルムコーティング錠 | |
JP7071538B2 (ja) | 医薬組成物 | |
JP2015212259A (ja) | ロスバスタチンまたはその塩の安定化製剤 | |
JP2022013875A (ja) | 医薬組成物 | |
HUE032635T2 (en) | For oral administration of pharmaceutical compositions having improved elution and / or absorbance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18825167 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019527072 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20197038643 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018825167 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2018825167 Country of ref document: EP Effective date: 20200130 |